{"id":"oxaliplatin-based-chemotherapy","safety":{"commonSideEffects":[{"rate":"76","effect":"Peripheral neuropathy"},{"rate":"64","effect":"Nausea and vomiting"},{"rate":"46","effect":"Diarrhea"},{"rate":"41","effect":"Neutropenia"},{"rate":"33","effect":"Anemia"},{"rate":"30","effect":"Thrombocytopenia"},{"rate":"61","effect":"Fatigue"},{"rate":"14","effect":"Stomatitis"}]},"_chembl":{"chemblId":"CHEMBL414804","moleculeType":"Small molecule","molecularWeight":"395.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oxaliplatin is a third-generation platinum compound that binds to DNA and forms interstrand and intrastrand crosslinks, preventing DNA replication and transcription in cancer cells. This leads to cell cycle arrest and apoptosis. Unlike earlier platinum agents, oxaliplatin has a unique diaminocyclohexane carrier ligand that may confer different toxicity and efficacy profiles.","oneSentence":"Oxaliplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to kill rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:03.493Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer (in combination with fluorouracil and leucovorin)"},{"name":"Adjuvant treatment of stage III colon cancer (in combination with fluorouracil and leucovorin)"},{"name":"Advanced ovarian cancer"},{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT04847063","phase":"PHASE1","title":"Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-19","conditions":"Peritoneal Mesothelioma, Peritoneal Carcinomatosis, Ovarian Cancer","enrollment":60},{"nctId":"NCT07283939","phase":"NA","title":"Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2026-02-13","conditions":"Ampulla of Vater Carcinoma, Appendix Carcinoma, Carcinoma of Unknown Primary With Gastrointestinal Profile","enrollment":420},{"nctId":"NCT05771480","phase":"PHASE3","title":"Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-08-16","conditions":"Biliary Tract Cancer","enrollment":142},{"nctId":"NCT05825066","phase":"PHASE2","title":"Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2023-08-01","conditions":"Pancreas Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma","enrollment":64},{"nctId":"NCT02758951","phase":"PHASE2, PHASE3","title":"Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Koen Rovers","startDate":"2017-06-01","conditions":"Colorectal Neoplasm, Colorectal Cancer, Colorectal Neoplasms Malignant","enrollment":358},{"nctId":"NCT07059494","phase":"PHASE4","title":"Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2026-06","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT07409987","phase":"NA","title":"The Effect of Electrostimulation and Compression Applications on Neuropathy Symptoms and Quality of Life in the Management of Chemotherapy-Induced Peripheral Neuropathy in Gastrointestinal System Cancer Patients Receiving Oxaliplatin-Based Treatment","status":"COMPLETED","sponsor":"Cumhuriyet University","startDate":"2025-01-02","conditions":"CIPN - Chemotherapy-Induced Peripheral Neuropathy, Oxaliplatin, Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients","enrollment":140},{"nctId":"NCT07043400","phase":"PHASE3","title":"A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-08-27","conditions":"Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":351},{"nctId":"NCT07483359","phase":"PHASE2","title":"Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus","status":"NOT_YET_RECRUITING","sponsor":"First Hospital of China Medical University","startDate":"2026-03","conditions":"Hepatocellular Carcinoma (HCC), Portal Vein Tumor Thrombus","enrollment":38},{"nctId":"NCT05379595","phase":"PHASE1, PHASE2","title":"A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-29","conditions":"Advanced or Metastatic Colorectal Cancer","enrollment":225},{"nctId":"NCT07044362","phase":"NA","title":"Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis","status":"RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2025-06-30","conditions":"Colorectal Cancer, Liver Metastases, Liver Cancer","enrollment":100},{"nctId":"NCT06258525","phase":"PHASE2","title":"SAMe in Prevention of Oxaliplatin-associated Liver Injury","status":"NOT_YET_RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2026-03","conditions":"Colorectal Cancer, Liver Metastases, Liver Metastasis Colon Cancer","enrollment":30},{"nctId":"NCT06731478","phase":"PHASE3","title":"Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2025-02-27","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":726},{"nctId":"NCT06256328","phase":"PHASE2","title":"A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2024-01-10","conditions":"Gastric Cancer","enrollment":226},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT06901531","phase":"PHASE3","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-05-22","conditions":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer","enrollment":500},{"nctId":"NCT04083235","phase":"PHASE3","title":"A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment","status":"COMPLETED","sponsor":"Ipsen","startDate":"2020-02-11","conditions":"Metastatic Adenocarcinoma of the Pancreas","enrollment":770},{"nctId":"NCT07333053","phase":"NA","title":"Clinical Efficacy of Transarterial Infusion Chemotherapy for Unresectable Colorectal Cancer","status":"RECRUITING","sponsor":"Quanda Liu","startDate":"2026-03-31","conditions":"Unresectable Colorectal Cancer","enrollment":30},{"nctId":"NCT07070466","phase":"PHASE2","title":"Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-10-10","conditions":"Stomach Cancer Stage IV, Esophagus Cancer, Stomach Cancer","enrollment":40},{"nctId":"NCT05174169","phase":"PHASE2, PHASE3","title":"Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2022-03-10","conditions":"Stage III Colon Cancer","enrollment":1912},{"nctId":"NCT06047379","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":"Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult","enrollment":134},{"nctId":"NCT05382559","phase":"PHASE1","title":"A Study of ASP3082 in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2022-06-08","conditions":"Solid Tumor","enrollment":681},{"nctId":"NCT06447662","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-06-27","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":330},{"nctId":"NCT07432022","phase":"PHASE1, PHASE2","title":"A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai EpimAb Biotherapeutics Co., Ltd.","startDate":"2026-03-01","conditions":"Combination Therapy, Aggressive B-Cell Non-Hodgkin Lymphoma, EMB07","enrollment":115},{"nctId":"NCT04430738","phase":"PHASE2","title":"Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2020-09-15","conditions":"Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma","enrollment":40},{"nctId":"NCT07184047","phase":"","title":"Frailty Scales for Predicting Chemotherapy Toxicity in Older Adults With Gastrointestinal Cancers","status":"COMPLETED","sponsor":"Ankara Etlik City Hospital","startDate":"2024-01-15","conditions":"Gastrointestinal Cancers, Frailty, Sarcopenia in Elderly","enrollment":72},{"nctId":"NCT04485013","phase":"PHASE1","title":"TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers","status":"RECRUITING","sponsor":"Tizona Therapeutics, Inc","startDate":"2020-07-14","conditions":"Cancer","enrollment":240},{"nctId":"NCT05475366","phase":"NA","title":"Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures","status":"RECRUITING","sponsor":"Institut Curie","startDate":"2022-12-12","conditions":"Carcinoma, Pancreatic Ductal, Prognosis","enrollment":85},{"nctId":"NCT05673772","phase":"PHASE2","title":"Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyungpook National University Hospital","startDate":"2020-10-23","conditions":"Rectal Cancer","enrollment":364},{"nctId":"NCT06501989","phase":"PHASE2","title":"Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer","status":"WITHDRAWN","sponsor":"Inova Health Care Services","startDate":"2025-09-19","conditions":"Metastatic Colorectal Cancer","enrollment":""},{"nctId":"NCT03362177","phase":"PHASE3","title":"Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-09-30","conditions":"Chemotherapy-induced Thrombocytopenia","enrollment":165},{"nctId":"NCT07399561","phase":"NA","title":"Effect of Exercise on Chemotherapy-Induced Peripheral Neuropathy","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2026-02-03","conditions":"Peripheral Neuropathy, Secondary to Drugs or Chemicals, Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients, Paclitaxel Induced Neuropathy","enrollment":140},{"nctId":"NCT07201519","phase":"PHASE2","title":"Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy","status":"RECRUITING","sponsor":"Michael J Cavnar, MD","startDate":"2026-01-23","conditions":"Colorectal Cancer Metastatic, Intrahepatic Cholangiocarcinoma","enrollment":80},{"nctId":"NCT07385703","phase":"PHASE3","title":"Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","startDate":"2026-03","conditions":"Adenocarcinoma","enrollment":752},{"nctId":"NCT06829771","phase":"PHASE1, PHASE2","title":"Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-23","conditions":"Diffuse Large B Cell Lymphoma","enrollment":90},{"nctId":"NCT06199232","phase":"NA","title":"Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking University","startDate":"2024-01-23","conditions":"Liver Metastasis Colon Cancer, ctDNA Genotype, MSS","enrollment":47},{"nctId":"NCT07312422","phase":"PHASE1, PHASE2","title":"LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study","status":"RECRUITING","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2025-09-30","conditions":"Pancreatic Cancer, PD-L1, PD-1 Inhibitor","enrollment":10},{"nctId":"NCT06510010","phase":"PHASE2","title":"Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2024-12-31","conditions":"Chemotherapy Effect","enrollment":198},{"nctId":"NCT07365592","phase":"PHASE1, PHASE2","title":"Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-01-01","conditions":"Colorectal Cancer","enrollment":138},{"nctId":"NCT06468280","phase":"PHASE2","title":"Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-11-08","conditions":"Gastric Cancer, GastroEsophageal Cancer","enrollment":84},{"nctId":"NCT04505553","phase":"PHASE2","title":"Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer","status":"COMPLETED","sponsor":"University of Washington","startDate":"2021-06-01","conditions":"Appendix Carcinoma, Colon Carcinoma, Esophageal Carcinoma","enrollment":78},{"nctId":"NCT07353827","phase":"PHASE2","title":"FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-01","conditions":"Intrahepatic Cholangiocarcinoma (Icc), Hepatic Arterial Infusion Chemotherapy","enrollment":36},{"nctId":"NCT06574620","phase":"NA","title":"Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment","status":"RECRUITING","sponsor":"British Columbia Cancer Agency","startDate":"2025-11-28","conditions":"Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma","enrollment":200},{"nctId":"NCT07042685","phase":"PHASE2","title":"Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-02","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":50},{"nctId":"NCT07332533","phase":"PHASE2, PHASE3","title":"A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2025-12-30","conditions":"HER2-positive Gastric Cancer","enrollment":490},{"nctId":"NCT07334587","phase":"NA","title":"Comparison of Efficacy and Safety Between FOLFOX-6 and CAPOX in Metastatic Colorectal Carcinoma","status":"ENROLLING_BY_INVITATION","sponsor":"Allama Iqbal Medical College","startDate":"2025-09-01","conditions":"Metastatic Colorectal Carcinoma (mCRC)","enrollment":248},{"nctId":"NCT07328087","phase":"EARLY_PHASE1","title":"COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer","status":"RECRUITING","sponsor":"Biogenea Pharmaceuticals Ltd.","startDate":"2026-02-02","conditions":"Colorectal Cancer Metastatic, Colorectal Cancer Stage III, Colorectal Cancer Stage IV","enrollment":12},{"nctId":"NCT05108428","phase":"EARLY_PHASE1","title":"Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-12-23","conditions":"Rectal Adenocarcinoma","enrollment":20},{"nctId":"NCT03322995","phase":"PHASE2","title":"Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2018-06-21","conditions":"Pancreatic Cancer","enrollment":125},{"nctId":"NCT07318805","phase":"PHASE1","title":"A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-12-16","conditions":"Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer","enrollment":260},{"nctId":"NCT05945823","phase":"PHASE2","title":"Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2023-07-13","conditions":"Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer","enrollment":53},{"nctId":"NCT07213557","phase":"PHASE2","title":"Simvastatin Efficacy in ARID1A Mutated Advanced gastroESophageal Carcinoma Treated With Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2025-12","conditions":"Advanced or Metastatic Gastrooesophageal Carcinoma","enrollment":84},{"nctId":"NCT07285356","phase":"NA","title":"Study to Evaluate the Use of Surgical Gloves for the Prevention of Oxaliplatin-Induced Peripheral Neuropathy","status":"RECRUITING","sponsor":"AC Camargo Cancer Center","startDate":"2025-10-06","conditions":"Colon Cancer, Oxaliplatin-induced Peripheral Neuropathy","enrollment":84},{"nctId":"NCT03281369","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-10-13","conditions":"Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma","enrollment":214},{"nctId":"NCT05111626","phase":"PHASE3","title":"Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2022-03-14","conditions":"Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":515},{"nctId":"NCT03615326","phase":"PHASE3","title":"Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-05","conditions":"Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma","enrollment":738},{"nctId":"NCT06245356","phase":"PHASE2","title":"Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-03-21","conditions":"Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma, DPD Deficiency","enrollment":73},{"nctId":"NCT06052332","phase":"NA","title":"Efficacy and Safety of Conventional Neoadjuvant Therapy Versus Total Neoadjuvant Therapy in Older Patients With Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Jules Bordet Institute","startDate":"2024-02-07","conditions":"Locally Advanced Rectal Cancer, Older People","enrollment":230},{"nctId":"NCT07267078","phase":"PHASE2","title":"Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-05-25","conditions":"Biliary Tract Cancer","enrollment":45},{"nctId":"NCT07257575","phase":"PHASE2","title":"A Randomized Controlled Study of Serplulimab Combined With Chemotherapy for Locally Advanced Gastric Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2025-01-05","conditions":"Gastric Cancer Stage III","enrollment":138},{"nctId":"NCT05025826","phase":"NA","title":"Study Evaluating Neurotoxicity in Patients With Metastatic Gastro Intestinal Cancer Taking Phycocare® or Placebo During Oxaliplatin Based Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2022-04-01","conditions":"Metastatic Gastric Cancer","enrollment":110},{"nctId":"NCT07072351","phase":"PHASE1, PHASE2","title":"Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-09-15","conditions":"Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy, Immunotherapy","enrollment":88},{"nctId":"NCT07243938","phase":"PHASE2","title":"Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)","status":"NOT_YET_RECRUITING","sponsor":"Tao Zhang","startDate":"2026-01-15","conditions":"Locally Advanced Rectal Cancer (LARC), Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (mCRC)","enrollment":70},{"nctId":"NCT04891289","phase":"PHASE2","title":"Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-05-07","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":164},{"nctId":"NCT03193190","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-07-05","conditions":"Pancreatic Adenocarcinoma","enrollment":341},{"nctId":"NCT03217097","phase":"NA","title":"MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2018-10-16","conditions":"Neuroendocrine Tumors","enrollment":116},{"nctId":"NCT07241403","phase":"","title":"Chronic Inflammation, Plasma Proteins Signature, Survival Outcomes and Clinical Response, in Patients Receiving Bevacizumab Combined With Oxaliplatin-based Chemotherapy (Bev/OX) or Bevacizumab Combined With Irinotecan-based Chemotherapy (Bev/IRI)","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2018-01-01","conditions":"Colorectal Cancer, Resistance, Bevacizimab","enrollment":698},{"nctId":"NCT07167446","phase":"EARLY_PHASE1","title":"Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy","status":"RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2025-10-14","conditions":"Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients, Metastatic Colorectal Cancer (CRC), Peripheral Neuropathy Due to Chemotherapy","enrollment":30},{"nctId":"NCT04363801","phase":"PHASE2","title":"A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer","status":"TERMINATED","sponsor":"Leap Therapeutics, Inc.","startDate":"2020-07-29","conditions":"Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer","enrollment":247},{"nctId":"NCT07198165","phase":"PHASE2","title":"SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-09-05","conditions":"Rectal Cancer, Rectal Adenocarcinoma, Rectal Cancer, Radiotherapy","enrollment":104},{"nctId":"NCT06896188","phase":"PHASE1","title":"9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)","status":"RECRUITING","sponsor":"Anwaar Saeed","startDate":"2025-09-22","conditions":"Pancreatic Adenocarcinoma","enrollment":12},{"nctId":"NCT06905509","phase":"PHASE2","title":"Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Joseph Tuscano","startDate":"2025-07-31","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements","enrollment":25},{"nctId":"NCT07188025","phase":"PHASE3","title":"ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2025-10","conditions":"Rectal Cancer","enrollment":103},{"nctId":"NCT05780684","phase":"NA","title":"Individualized Dose Escalation of 5-FU for Gastrointestinal Cancer","status":"RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2023-07-14","conditions":"Colorectal Cancer, Esophagus Cancer, Appendix Cancer","enrollment":36},{"nctId":"NCT07175636","phase":"PHASE2","title":"QL1706 With Short-Course Radiotherapy and Chemotherapy for MSS Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-09-20","conditions":"Locally Advanced Rectal Cancer (LARC), Mismatch Repair-Proficient (pMMR) Rectal Cancer, Non-metastatic Rectal Cancer","enrollment":66},{"nctId":"NCT07173387","phase":"PHASE2","title":"Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer: A Prospective Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-10-01","conditions":"Pancreatic Cancer","enrollment":42},{"nctId":"NCT03773367","phase":"PHASE2","title":"Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lund University Hospital","startDate":"2018-12-14","conditions":"Resectable Gastric and Gastroesophageal Junction Adenocarcinoma","enrollment":60},{"nctId":"NCT05107674","phase":"PHASE1","title":"A Study of NX-1607 in Adults With Advanced Malignancies","status":"RECRUITING","sponsor":"Nurix Therapeutics, Inc.","startDate":"2021-09-29","conditions":"Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer","enrollment":345},{"nctId":"NCT05990543","phase":"PHASE1, PHASE2","title":"Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Korea University Anam Hospital","startDate":"2024-01-29","conditions":"Recurrent or Metastatic Colorectal Cancer","enrollment":59},{"nctId":"NCT07007182","phase":"PHASE2","title":"Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jinbo Yue","startDate":"2025-10-01","conditions":"Gastric Adenocarcinoma, Stomach Neoplasms","enrollment":54},{"nctId":"NCT07156058","phase":"NA","title":"MiniPDX-based Postoperative Adjuvant Therapy for Biliary Tract Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-01-01","conditions":"Biliary Tract Cancer","enrollment":204},{"nctId":"NCT06490536","phase":"PHASE3","title":"The Sagittarius Trial","status":"RECRUITING","sponsor":"IFOM ETS - The AIRC Institute of Molecular Oncology","startDate":"2024-10-22","conditions":"Colon Cancer Stage II, Colon Cancer Stage III","enrollment":700},{"nctId":"NCT03170960","phase":"PHASE1","title":"Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2017-09-05","conditions":"Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer","enrollment":914},{"nctId":"NCT07098949","phase":"NA","title":"Acupuncture Combined With Chemotherapy for Gastric Cancer After Surgery","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2025-08","conditions":"Gastric Cancer","enrollment":346},{"nctId":"NCT06839092","phase":"PHASE3","title":"Prophylactic PIPAC in Patients With High-risk Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jeremy Meyer","startDate":"2026-01","conditions":"Colorectal Cancer Control and Prevention, Colorectal Cancer, Colorectal Cancer Stage II","enrollment":160},{"nctId":"NCT05850130","phase":"NA","title":"Acupuncture for Oxaliplatin-induced Peripheral Neuropathy in Gastro-intestinal Cancer Patients","status":"RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2023-11-22","conditions":"Colorectal Cancer, Liver Cancer, Gastric Cancer","enrollment":182},{"nctId":"NCT05132504","phase":"PHASE2","title":"Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2022-08-31","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":30},{"nctId":"NCT03828227","phase":"PHASE3","title":"QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters.","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2019-06-14","conditions":"Elderly Patients, Metastatic Colorectal Cancer, Quality of Life","enrollment":49},{"nctId":"NCT06873763","phase":"PHASE1, PHASE2","title":"Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer","status":"RECRUITING","sponsor":"STCube, Inc.","startDate":"2025-06-09","conditions":"Metastatic Colorectal Cancer (CRC), Recurrent Colorectal Cancer","enrollment":52},{"nctId":"NCT06719362","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies","status":"RECRUITING","sponsor":"Providence Health & Services","startDate":"2025-06-17","conditions":"Advanced Solid Tumors","enrollment":110},{"nctId":"NCT07053150","phase":"PHASE2","title":"A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-15","conditions":"Advanced Digestive System Tumor","enrollment":80},{"nctId":"NCT04594772","phase":"PHASE2","title":"Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cincinnati","startDate":"2021-03-17","conditions":"Pancreas Cancer","enrollment":32},{"nctId":"NCT06939439","phase":"PHASE3","title":"Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-12-01","conditions":"Gastric Cancer Stage III","enrollment":416},{"nctId":"NCT07030140","phase":"PHASE2","title":"Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Jinbo Yue","startDate":"2025-07-01","conditions":"Cholangiocarcinoma, Hilar Cholangiocarcinoma, Bile Duct Cancer","enrollment":38},{"nctId":"NCT06728657","phase":"PHASE2","title":"Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma","status":"SUSPENDED","sponsor":"Fudan University","startDate":"2024-07-01","conditions":"Stomach Adenocarcinoma, Gastro-esophageal Junction Cancer","enrollment":68},{"nctId":"NCT05118724","phase":"PHASE2","title":"Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin","status":"ACTIVE_NOT_RECRUITING","sponsor":"AIO-Studien-gGmbH","startDate":"2021-12-10","conditions":"Colorectal Cancer","enrollment":80},{"nctId":"NCT07018063","phase":"PHASE2","title":"Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"zhoujing","startDate":"2025-10-01","conditions":"Gastric (Cardia, Body) Cancer, Stomach Adenocarcinoma, Locally Advanced","enrollment":35},{"nctId":"NCT05929885","phase":"PHASE2","title":"Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients","status":"RECRUITING","sponsor":"National Cancer Centre, Singapore","startDate":"2023-08-30","conditions":"Metastatic Pancreatic Cancer","enrollment":50},{"nctId":"NCT05851924","phase":"PHASE2","title":"A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-05-12","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":60},{"nctId":"NCT04861558","phase":"PHASE3","title":"Efficacy of Hyperthermic Intraperitoneal Chemotherapy","status":"RECRUITING","sponsor":"Uppsala University","startDate":"2021-05-01","conditions":"Colorectal Cancer, Peritoneal Metastases","enrollment":213}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":800,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["FOLFOX 4","FOLFOX 5","Modified FOLFOX 6","FOLFOX 7","Oxaliplatin"],"phase":"phase_3","status":"active","brandName":"Oxaliplatin Based Chemotherapy","genericName":"Oxaliplatin Based Chemotherapy","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oxaliplatin is a small molecule DNA inhibitor used in chemotherapy, classified as an inhibitor. It is studied for various conditions, including Advanced Breast Cancer, Metastatic Breast Cancer, Colorectal Cancer, and Metastatic Colorectal Adenocarcinoma, among others.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}